Literature DB >> 30152044

Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.

Elisabet Augé1,2, Carme Pelegrí1,2,3, Gemma Manich1, Itsaso Cabezón1,2, Joan J Guinovart4,5,6, Jordi Duran4,5, Jordi Vilaplana1,2,3.   

Abstract

Lafora disease (LD), the most devastating adolescence-onset epilepsy, is caused by mutations in the EPM2A or EPM2B genes, which encode the proteins laforin and malin, respectively. Loss of function of one of these proteins, which are involved in the regulation of glycogen synthesis, induces the accumulation of polyglucosan bodies (PGBs)-known as Lafora bodies (LBs) and associated with neurons-in the brain. Ageing and some neurodegenerative conditions lead to the appearance of another type of PGB called corpora amylacea, which are associated with astrocytes and contain neo-epitopes that can be recognized by natural antibodies. Here we studied the PGBs in the cerebral cortex and hippocampus of malin knockout mice, a mouse model of LD. These animals presented not only LBs associated with neurons but also a significant number of PGBs associated with astrocytes. These astrocytic PGBs were also increased in mice from senescence-accelerated mouse-prone 8 (SAMP8) strain and mice with overexpression of Protein Targeting to Glycogen (PTGOE ), indicating that they are not exclusive of LD. The astrocytic PGBs, but not neuronal LBs, contained neo-epitopes that are recognized by natural antibodies. The astrocytic PGBs appeared predominantly in the hippocampus but were also present in some cortical brain regions, while neuronal LBs were found mainly in the brain cortex and the pyramidal layer of hippocampal regions CA2 and CA3. Our results indicate that astrocytes, contrary to current belief, are involved in the etiopathogenesis of LD.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990corpora amylacea; Lafora body; malin; natural antibody; neo-epitope

Mesh:

Substances:

Year:  2018        PMID: 30152044      PMCID: PMC6240358          DOI: 10.1002/glia.23463

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  63 in total

Review 1.  Natural IgM antibodies against oxidation-specific epitopes.

Authors:  Christoph J Binder
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice.

Authors:  T A Robertson; N S Dutton; R N Martins; A D Roses; B A Kakulas; J M Papadimitriou
Journal:  Neuroscience       Date:  1998-01       Impact factor: 3.590

3.  A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).

Authors:  J M Serratosa; P Gómez-Garre; M E Gallardo; B Anta; D B de Bernabé; D Lindhout; P B Augustijn; C A Tassinari; R M Malafosse; M Topcu; D Grid; C Dravet; S F Berkovic; S R de Córdoba
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

4.  Similarities in the age-related hippocampal deposition of periodic acid-schiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains.

Authors:  H Kuo; D K Ingram; L C Walker; M Tian; J M Hengemihle; M Jucker
Journal:  Neuroscience       Date:  1996-10       Impact factor: 3.590

5.  Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease.

Authors:  Rajat Puri; Toshimitsu Suzuki; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

6.  New data on the ultrastructure of the corpus amylaceum (polyglucosan body).

Authors:  L Leel-Ossy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

7.  Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin.

Authors:  Sudheendra N R Rao; Ranjan Maity; Jaiprakash Sharma; Parthanarayan Dey; Susarla Krishna Shankar; Parthasarathy Satishchandra; Nihar Ranjan Jana
Journal:  Hum Mol Genet       Date:  2010-09-21       Impact factor: 6.150

8.  Grading score system: a method for evaluation of the degree of senescence in senescence accelerated mouse (SAM).

Authors:  M Hosokawa; R Kasai; K Higuchi; S Takeshita; K Shimizu; H Hamamoto; A Honma; M Irino; K Toda; A Matsumura
Journal:  Mech Ageing Dev       Date:  1984-07       Impact factor: 5.432

9.  The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.

Authors:  Punitee Garyali; Pratibha Siwach; Pankaj Kumar Singh; Rajat Puri; Shuchi Mittal; Sonali Sengupta; Rashmi Parihar; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2008-11-25       Impact factor: 6.150

10.  Periodic acid-Schiff (PAS)-positive, granular structures increase in the brain of senescence accelerated mouse (SAM).

Authors:  H Akiyama; M Kameyama; I Akiguchi; H Sugiyama; T Kawamata; H Fukuyama; H Kimura; M Matsushita; T Takeda
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

View more
  24 in total

1.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

2.  Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.

Authors:  Grant L Austin; Zoe R Simmons; Jack E Klier; Alberto Rondon; Brad L Hodges; Robert Shaffer; Nadine M Aziz; Tracy R McKnight; James R Pauly; Dustin D Armstrong; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Pharm       Date:  2019-08-02       Impact factor: 4.939

3.  Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.

Authors:  Belén Mollá; Miguel Heredia; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2021-01-14       Impact factor: 5.590

Review 4.  The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic.

Authors:  Matthew S Gentry; Zaid Afawi; Dustin D Armstrong; Antonio Delgado-Escueta; Y Paul Goldberg; Tamar R Grossman; Joan J Guinovart; Frank Harris; Thomas D Hurley; Roberto Michelucci; Berge A Minassian; Pascual Sanz; Carolyn A Worby; Jose M Serratosa
Journal:  Epilepsy Behav       Date:  2020-01-10       Impact factor: 2.937

5.  Polyglucosan body structure in Lafora disease.

Authors:  M Kathryn Brewer; Jean-Luc Putaux; Alberto Rondon; Annette Uittenbogaard; Mitchell A Sullivan; Matthew S Gentry
Journal:  Carbohydr Polym       Date:  2020-04-14       Impact factor: 9.381

Review 6.  Brain Glycogen Structure and Its Associated Proteins: Past, Present and Future.

Authors:  M Kathryn Brewer; Matthew S Gentry
Journal:  Adv Neurobiol       Date:  2019

Review 7.  Glycogen in Astrocytes and Neurons: Physiological and Pathological Aspects.

Authors:  Jordi Duran; Agnès Gruart; Juan Carlos López-Ramos; José M Delgado-García; Joan J Guinovart
Journal:  Adv Neurobiol       Date:  2019

Review 8.  Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.

Authors:  Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry
Journal:  Trends Mol Med       Date:  2019-09-12       Impact factor: 11.951

9.  Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease.

Authors:  Saija Ahonen; Silvia Nitschke; Tamar R Grossman; Holly Kordasiewicz; Peixiang Wang; Xiaochu Zhao; Dikran R Guisso; Sahba Kasiri; Felix Nitschke; Berge A Minassian
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

10.  Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity.

Authors:  Olga Varea; Jordi Duran; Mònica Aguilera; Neus Prats; Joan J Guinovart
Journal:  Neurobiol Dis       Date:  2020-11-07       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.